A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-term extension period - Trial 2022-000049-34

Name: Clinical Trial 2022-000049-34
Creator: SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
Keywords: Multiple sclerosis, clinical trial

Access comprehensive clinical trial information for 2022-000049-34 through Pure Global AI's free database. This phase not specified trial is sponsored by SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT and is currently Ongoing. The study focuses on Multiple sclerosis.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2022-000049-34

Ongoing

Trial Details

EU Clinical Trials Register • 2022-000049-34

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-term extension period

Study Focus

Disease/Condition

Multiple sclerosis

Sponsor & Location

Primary Sponsor

SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT

Funder

Sanofi-Aventis recherche & développement

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

Participants are excluded from the study if any of the following criteria apply:

ICD-10 Classifications

Multiple sclerosis

Progressive systemic sclerosis

Systemic sclerosis

Systemic sclerosis, unspecified

Diffuse sclerosis

Data Source

Registry

EU Clinical Trials Register

Trial ID

2022-000049-34

Type

Non-Device Trial